Kishan Parikh, MD
Advanced Heart Failure and Transplant Cardiology · Raleigh, NCNPI 1780813782
Payments from drug & device makers
Across 360 payments — averaging $882.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$88K
- Janssen Research & Development, LLC$83K
- Merck$50K
- Amgen$30K
- Boehringer Ingelheim Pharma GmbH & Co.kg$27K
- Actelion Pharmaceuticals US, Inc.$15K
- plus $25K from 25 others
Across 6 payments — averaging $188.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 122 | $88,462 |
| Janssen Research & Development, LLC | 15 | $83,105 |
| Merck | 63 | $49,742 |
| Amgen | 7 | $30,199 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $26,708 |
| Actelion Pharmaceuticals US, Inc. | 23 | $14,816 |
| Boehringer Ingelheim International GmbH | 40 | $7,190 |
| Boehringer Ingelheim | 10 | $5,594 |
| Boston Scientific | 3 | $4,400 |
| Lilly USA, LLC | 2 | $2,850 |
| Bayer | 4 | $2,075 |
| EKOS Corporation | 1 | $1,000 |
| AstraZeneca | 9 | $233 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $211 |
| Abbott | 5 | $189 |
| Novartis | 7 | $143 |
| Edwards Lifesciences | 2 | $99 |
| Bridgebio Pharma, Inc. | 4 | $88 |
| Pfizer | 4 | $82 |
| E.r. Squibb & Sons, L.L.C. | 3 | $76 |
| Alnylam Pharmaceuticals Inc. | 3 | $69 |
| Impulse Dynamics (USA) Inc. | 3 | $69 |
| Novo Nordisk | 2 | $50 |
| Abiomed | 2 | $49 |
| Johnson & Johnson | 2 | $46 |
| Endotronix, Inc. | 1 | $29 |
| Bristol Myers Squibb | 1 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Kestra Medical Technology Services, Inc. | 1 | $21 |
| Heartflow, Inc. | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $15 |
How this compares
$317,675 in reported general payments places this provider in the 75th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.
See all advanced heart failure and transplant cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other advanced heart failure and transplant cardiology in Raleigh
- David IshizawarRaleigh$1.2M
- Stuart RussellRaleigh$211K
- Daniel BensimhonGreensboro$2.5M
- Stephen GreeneDurham$737K
- Dalton McLeanGreensboro$706K
- Emil MissovGreenville$582K
- Hassan AlhosainiWinston Salem$394K
- John RommelWilmington$394K
- Stephen ZouzoulasConcord$244K
- Benjamin TrichonAsheville$233K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.